Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 236Lymphoma 176Lymphoma, Large B-Cell, Diffuse 171Precursor Cell Lymphoblastic Leukemia-Lymphoma 84Lymphoma, Follicular 77Lymphoma, Non-Hodgkin 72Burkitt Lymphoma 66Multiple Myeloma 62Leukemia 57Hodgkin Disease 45Lymphoma, Mantle-Cell 41Neoplasms 34Lymphoma, T-Cell, Peripheral 31Lymphoma, B-Cell 30Lymphoma, B-Cell, Marginal Zone 27Lymphoma, Large-Cell, Anaplastic 26Lymphoma, Large-Cell, Immunoblastic 24Neoplasm Metastasis 23Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Neoplasms, Plasma Cell 21Recurrence 19Immunoblastic Lymphadenopathy 15Dendritic Cell Sarcoma, Interdigitating 15Lymphoma, T-Cell 14Leukemia, Biphenotypic, Acute 10Waldenstrom Macroglobulinemia 9Blast Crisis 9Primary Myelofibrosis 8Myelodysplastic Syndromes 8

Interventions

enzalutamide 7Abiraterone Acetate 4abiraterone 3Prednisone 3Docetaxel 3sapanisertib 1relugolix 1pembrolizumab 1onvansertib 1olaparib 1lenvatinib 1inavolisib 1belzutifan 1apalutamide 1abemaciclib 1Prednisolone 1PF06821497 1Methylprednisolone 1Lutetium-177 1Lutetium 1Gonadotropin-Releasing Hormone 1Etoposide 1Dexamethasone 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Metastatic Castration-Resistant Prostate Cancer × Prednisone × Clear all
NCT02861573 2026-02-17

KEYNOTE-365

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
1,200 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
48 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT03414034 2024-11-07

Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Cardiff Oncology

Phase 2 Completed
72 enrolled 21 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡